CL2020000127A1 - Therapeutic modulators of the reverse mode of atp synthase. - Google Patents

Therapeutic modulators of the reverse mode of atp synthase.

Info

Publication number
CL2020000127A1
CL2020000127A1 CL2020000127A CL2020000127A CL2020000127A1 CL 2020000127 A1 CL2020000127 A1 CL 2020000127A1 CL 2020000127 A CL2020000127 A CL 2020000127A CL 2020000127 A CL2020000127 A CL 2020000127A CL 2020000127 A1 CL2020000127 A1 CL 2020000127A1
Authority
CL
Chile
Prior art keywords
atp synthase
reverse mode
therapeutic modulators
atp
modulators
Prior art date
Application number
CL2020000127A
Other languages
Spanish (es)
Inventor
Michael David Forrest
Original Assignee
Michael David Forrest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1711250.9A external-priority patent/GB201711250D0/en
Priority claimed from PCT/EP2018/051127 external-priority patent/WO2018134265A1/en
Priority claimed from GBGB1806421.2A external-priority patent/GB201806421D0/en
Application filed by Michael David Forrest filed Critical Michael David Forrest
Publication of CL2020000127A1 publication Critical patent/CL2020000127A1/en

Links

Abstract

LOS COMPUESTOS DE LA SIGUIENTE FÓRMULA (I) RALENTIZAN EL MODO DE HIDROLIZACIÓN DE ATP DE LA ATP SINTASA Y SON ÚTILES PARA TRATAR DIVERSAS ENFERMEDADES Y TRASTORNOS, INCLUIDO EL CÁNCER, PARTICULARMENTE LOS CÁNCERES QUE UTILIZAN EL EFECTO WARBURG.THE COMPOUNDS IN THE FOLLOWING FORMULA (I) SLOW THE ATP HYDROLYZATION MODE OF ATP SYNTHASE AND ARE USEFUL TO TREAT VARIOUS DISEASES AND DISORDERS, INCLUDING CANCER, PARTICULARLY THE CANCURS USED BY WARB EFFECT.

CL2020000127A 2017-07-13 2020-01-16 Therapeutic modulators of the reverse mode of atp synthase. CL2020000127A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1711250.9A GB201711250D0 (en) 2017-07-13 2017-07-13 Cancer therapy
PCT/EP2018/051127 WO2018134265A1 (en) 2017-01-17 2018-01-17 Therapeutic inhibitors of the reverse mode of atp synthase
GBGB1806421.2A GB201806421D0 (en) 2018-04-19 2018-04-19 Disclosure

Publications (1)

Publication Number Publication Date
CL2020000127A1 true CL2020000127A1 (en) 2020-04-24

Family

ID=70457154

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000127A CL2020000127A1 (en) 2017-07-13 2020-01-16 Therapeutic modulators of the reverse mode of atp synthase.

Country Status (1)

Country Link
CL (1) CL2020000127A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11649238B2 (en) 2018-01-17 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof
US11649238B2 (en) 2018-01-17 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors

Similar Documents

Publication Publication Date Title
ECSP20020410A (en) ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES OF THE SAME
CL2018001685A1 (en) Heterocyclic compounds as immuno modulators.
CO2019007863A2 (en) Benzooxazole derivatives as immunomodulators
CL2019001709A1 (en) Pyrazole derivatives as malt1 inhibitors.
EA201990665A1 (en) HPK1 REGULATORS BASED ON PYRAZOLOPYRIDINE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF CANCER
ECSP20033467A (en) MACROCYCLIC COMPOUNDS TO TREAT DISEASES
PE20191474A1 (en) AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
BR112017024384A2 (en) bacteria modified to reduce hyperphenylalaninemia
CL2016001082A1 (en) Process for the synthesis of an indolamine 2,3-dioxygenase inhibitor
CL2020001797A1 (en) Compounds, compositions and methods for treating diseases involving tissues with acidic or hypoxic diseases.
CL2017000290A1 (en) Protein kinase c inhibitors and methods of their use.
CO2020002961A2 (en) Pyruvate kinase activators for use in the treatment of blood disorders
GT201400222A (en) AGENTS TO TREAT DISORDERS THAT INVOLVE THE MODULATION OF RIANODINE RECEPTORS
CO2020001107A2 (en) Therapeutic modulators of the reverse mode of atp synthase
UY37466A (en) N-HYDROXIAMIDINHETEROCICLES SUBSTITUTED AS MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE
DOP2016000308A (en) COMPOUNDS OF 1, 3, 4-TIADIAZOL AND USE OF THE SAME FOR THE TREATMENT OF CANCER
NI202000029A (en) SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND THEIR USE
CO2017000552A2 (en) Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
EA201791814A1 (en) IMIDAZOLYL TRYCYCLIC ENONS AS ANTIOXIDANT INFLAMMATION MODULATORS
CL2020000127A1 (en) Therapeutic modulators of the reverse mode of atp synthase.
CL2019002480A1 (en) Pyrazole derivatives as bromodomain inhibitors.
CL2020000586A1 (en) Modulators of enac expression.
PE20181450A1 (en) 1,3,4-THADIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CL2022003206A1 (en) Quinolone-derived compounds and their use for the treatment of cancer (div. sol. 202102501)
NI201500172A (en) PHARMACEUTICAL COMPOSITIONS